Die Suchmaschine für Unternehmensdaten in Europa
EU-Förderung (3.913.940 €): Mastering Skills im Ausbildungsnetzwerk für Aufmerksamkeitsdefizit-Hyperaktivität und Autismus-Spektrum-Störungen Hor 01.01.2015 EU-Rahmenprogramm für Forschung und Innovation "Horizont"
Auf einen Blick
Text
Mastering Skills im Ausbildungsnetzwerk für Aufmerksamkeitsdefizit-Hyperaktivität und Autismus-Spektrum-Störungen
Attention deficit/hyperactivity disorder (ADHD) and autism spectrum disorders (ASD) are frequent, chronic and highly heritable neurodevelopmental disorders. Despite their societal importance, progress in understanding disease biology has been slow and no curative treatment options are available. The pan-European training network MiND aims to educate a new generation of researchers in the field of neurodevelopmental disorders, through innovation-oriented research combined with highly interdisciplinary and intersectoral international training. Research and training in MiND span state-of-the-art topics in the fields of ADHD, ASD and their yet un-investigated overlap. We combine advanced (epi-)genetics approaches with bioinformatics and develop novel cell and animal models of increasing complexity to understand pathomechanisms. Integrated with research in large human DNA-neuroimaging-cognition data sets, we push forward the understanding of the biology leading from gene to cognition and disease. Our mechanistic work is embedded in a framework exploring alternative disease definitions for ADHD and ASD across the lifespan and working towards improved treatment: we use novel cognitive assessments, we probe the microbiome for dietary interventions reducing symptoms and evaluate mindfulness training as non-pharmacological treatment options, in addition to developing new compounds for pharmacological treatment optimization and individualization. The strategic collaboration of world-leading academic groups, research-intensive commercial enterprises and patient organisations will deliver 15 young, scientifically excellent researchers which are optimally prepared for private sector and academic careers. MiND can be expected to impact patients and society by improving our understanding of disease biology, by developing novel diagnostic and treatment strategies, and by raising awareness for the necessity of research of neurodevelopmental disorders from childhood to adulthood.
Geförderte Unternehmen:
| Firmenname | Förderungssumme |
| Adhd-Europe | ? |
| Braingaze SL | 123.936 € |
| Eurofins Medigenomix GmbH | 62.304 € |
| Fundacio Centre de Regulacio Genomica | 185.905 € |
| Fundacio Hospital Universitari Vall D'Hebron - Institut de Recerca | 123.936 € |
| Johann Wolfgang Goethe-Universitaet Frankfurt AM Main | 436.129 € |
| Karolinska Institutet | 263.659 € |
| King's College London | 478.254 € |
| Stichting Karakter | 255.374 € |
| Stichting Radboud Universiteit | 766.123 € |
| Universitaetsklinikum Wuerzburg - Klinikum DER Bayerischen Julius-Maximilians-Universitat | 124.608 € |
| Universitat de Barcelona | 247.873 € |
| Universitetet I Bergen | 572.550 € |
| University of Leicester | 273.288 € |
Quelle: https://cordis.europa.eu/project/id/643051
Diese Bekanntmachung wurde von Englisch nach Deutsch übersetzt. Die Bekanntmachung bezieht sich auf einen vergangenen Zeitpunkt, und spiegelt nicht notwendigerweise den heutigen Stand wider. Der letzte verfügbare Stand wird auf folgender Seite wiedergegeben: Adhd-Europe.
